Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. involving ADU-1805, an innovative anti-SIRP? antibody ...
Immune aging is a degenerative change in the immune ... but also enhance the sensibility of PD-1 blockade-based immunotherapy. PD-1/PD-L1 immune checkpoint blockade therapy has become a major ...
Thirteen proteins linked to brain aging in humans are identified in ... can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors. "This is your brain on drugs," the old ...
Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...
There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...
The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.
"We found that people born with a deficiency in PD-1 or PD-L1 have reduced diversity in their antibodies and fewer memory B cells, which made it harder to generate high-quality antibodies against ...
Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an N-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B ...
A+E Networks Settles ‘Live PD’ Lawsuit, Seals New Distribution Deal With Amazon as Part of Agreement
A+E Networks has settled its “Live PD” dispute with Amazon-owned Big Fish Entertainment and Reelz. As part of the settlement, A+E and Amazon have struck a new multi-year licensing deal on A+E ...
Recently, scientists at Stanford University began to wonder why identical lab mice, bred with the same DNA and brought up in identical conditions, wound up so different in their old age.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results